Last updated: Nov 16, 2026, 12:00 AM

Aran Research and Development 1982 Ltd Exchange (TA, ILA)

ARAN.TA

42.52
-1.03 (-2.37%)
IndustrialsConglomerates
Invest Today
Invest Today
1 year return (CAGR)
45.52%
3 year return (CAGR)
32.84%
5 year return (CAGR)
14.69%
10 year return (CAGR)
4.31%
Stock Analysis

Adobe 2026 Q3 – Is sentiment driving the price?

Read More
Marketcap
192.61M
Price/Sales
0.48
Ent value
262.67M
Price/Book
1.97
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
59.95%
Trailing P/E
7.53
PEG
-
Forward P/E
-
EPS growth
45.99%

Stock information

iO Charts Blog

What is a stock exchange? Operation, actors, examples

Read More

Stock chart

Loading...
Stock price data
Open43.58
Daily high44.49
Daily low42.52
Daily Volume0K
All-time high3531.00
1y analyst estimate-
Beta0.46
EPS (TTM)5.62
Dividend per share0.00
Ex-div date23 Mar 2026
Next earnings date-

Ready to capitalize on Aran Research and Development 1982 Ltd's growth potential?

Take the next step in your portfolio.

Invest Today

Downside potential

Loading...
Downside potential data
ARAN.TAS&P500
Current price drop from All-time high-98.80%-2.82%
Highest price drop-99.22%-56.47%
Date of highest drop8 Oct 20259 Mar 2009
Avg drop from high-44.63%-10.64%
Avg time to new high66 days12 days
Max time to new high3060 days1805 days
News
Novartis recently reported a positive CHMP opinion for Cosentyx in adolescents with moderate to severe hidradenitis suppurativa and 52 week Phase III data for Rhapsido in chronic inducible urticaria s...
November 16, 2026
Novartis (SWX:NOVN) is back in focus after a positive opinion from the European Medicines Agency’s CHMP for Cosentyx in adolescent hidradenitis suppurativa, highlighting how new indications can shape ...
November 16, 2026
Novartis (SWX:NOVN) received a positive CHMP opinion for Cosentyx in adolescents with hidradenitis suppurativa in Europe. The decision positions Cosentyx as a potential first new biologic option in ne...
November 16, 2026
Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium – 16 November 2026, 17.45 hrs CET Melexis reports the purchase of 36,700 Melexis shares on Euronext B...
November 16, 2026
Novo secures EC approval for Frehemgo while CagriSema delivers up to 21% weight loss, adding momentum to its turnaround efforts amid intensifying obesity drug competition.
November 16, 2026
NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.
November 16, 2026
Here is how Novartis (NVS) and Alpha Cognition Inc. (ACOG) have performed compared to their sector so far this year.
November 16, 2026
If you only glanced at Siam Cement during a year of mixed earnings headlines and heated debates about environmental costs, the outcome may surprise you. Holding Siam Cement over the past year would ha...
November 16, 2026
The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
November 16, 2026
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop...
November 16, 2026